|Title:||Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy||Authors:||Chen, Guan-Jhou
|Keywords:||Genetic barrier; Integrase strand transfer inhibitor; Nucleoside reverse transcriptase inhibitor; Resistance-associated mutation; Virological failure||Issue Date:||13-Feb-2021||Journal Volume:||105||Source:||International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases||Abstract:||
The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).
|Appears in Collections:||醫學檢驗暨生物技術學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.